Andrew Mortlock

🔬 Discover DuetMab Technology with evitria DuetMab is a cutting-edge bispecific antibody format designed to address the challenges of antibody engineering with a very specific approach. How DuetMab Works: DuetMab technology achieves correct heavy-light chain pairing by replacing the native disulfide bond in one of the CH1-CL interfaces with an engineered disulfide bond at a different location. This method significantly reduces the risk of mispairing, a common issue in bispecific antibody production, and ensures stable and effective antibody assembly. At evitria, we are specialized in producing various bispecific antibody formats, including DuetMab. But not only do we express them; we can also support our customers in choosing the ideal bsAb format for their project. Have you already made your own experiences with this format? Let us know in the comments! #DuetMab #BispecificAntibodies #Biotechnology #MedicalInnovation #AntibodyEngineering #evitria

15

Having trouble figuring out how to register your stall for Pharma Festives 3.0? 🤨 Don’t stress, here’s a simple guide to help you reserve your stall.

3

BioGlyph and Dotmatics building the Next-Generation of workflows for Multispecific Antibodies

59

Our latest whitepaper explores lab automation solutions available to CROs and CDMOs ✅ This includes the benefits they can bring and how true infrastructure-level automation can revolutionise the lab experience for everyone - from scientists to clients to patients. Download the ungated content here, no catch ➡️ bit.ly/44tSgwb #CROs #LabAutomation #Whitepaper

7

Imagine off-the-shelf NK cell therapies that are safe, potent, and available to all. This iPSC breakthrough brings us closer to that reality! Learn how this optimized process could change everything. Download the poster by Bio-Techne. https://lnkd.in/eW6797RZ #cancer #futureofmedicine #celltherapy #immunotherapy

3

#iPSCs, with their promise and complexity, are shaping the future of advanced cell therapies. They present unique challenges and opportunities in gene-editing, including the integration of CRISPR technology for iPSC-derived allogeneic cell therapies. Gain valuable insights into the challenges of employing gene-editing techniques for iPSC-derived therapies from Suzanne Snellenberg, Cellistic's VP of Cell Line Development. Read the full article at the link below and feel to reach out for more information! 💡🔗 https://hubs.ly/Q02xctr80 #iPSCs #GeneEditing #article

113

2 Comments

Patients can’t benefit from what they don’t understand. Don’t let poor communication keep your solution from reaching the right patients. 🩺 Rheumatology innovators Patiently’s engagement solution ensures your innovative treatment connects with the patients who need it most. 💡 Drop the name of your solution and the disease you’re solving in the comments, and let’s make sure the right patients find your breakthrough. 🚀 #Rheumatology #HealthTech #PatientEngagement #RightPatientRightCare #InnovativeHealthcare #MedTech #DigitalHealth #HealthcareInnovation #Patiently

1

Providing you the tools for your drug development needs. From research innovation to GMP excellence. Discover the difference with Avanti Research 

9

In the latest issue of Drug Development & Delivery , Dr Suzanne Saffie-Siebert and her team review the current shortcomings and accompanying manufacturing challenges of lipid nanoparticles, and they show how these shortcomings can be addressed by SiSaf’s silicon-stabilized hybrid LNPs (#sshLNPs). ⬇️Read the article https://lnkd.in/dGXT22va 🔗 Learn more about SiSaf and our Bio-Courier technology: sisaf.com #RNA #LNP #sshLNP #BioCourier

31

Discover how monitoring tumor fraction (TF) provides crucial insights into treatment response further reinforcing the value of our next-generation, tissue-free, actionable MRD assay, PredicineBEACON™, in tracking and predicting therapeutic efficacy within Roche's clinical trials for the KRAS G12C inhibitor, Divarasib, in this major breakthrough publication in Clinical Cancer Research, which builds on the significant findings from our previous studies in The New England Journal of Medicine and Nature Medicine.    Our latest study offers deep insights into circulating tumor DNA (ctDNA), specifically examining tumor fraction (TF) and KRAS G12C mutant allele frequency (AF). The analysis of baseline ctDNA profiles and the rapid dynamics observed in patients responding to Divarasib demonstrate a strong correlation with improved treatment outcomes.      Key Highlights:  • Tissue free, baseline blood informed MRD Profiling.   • Therapeutic response and PFS has been captured by PredicineBEACON™ MRD analysis.  • Tumor Fraction is precisely captured by PredicineBEACON™ MRD assay, which is further confirmed by the PredicineWES+™ across whole exome.   • PredicineBEACON™ identified ultra-low frequency ctDNA dynamic, offering clinical potential for treatment monitoring and resistance mechanisms.    PredicineBEACON™ continues to push the boundaries of precision oncology, delivering crucial molecular insights that propel the development and broader adoption of groundbreaking therapies such as Divarasib. Explore how our cutting-edge technology is shaping the future of cancer treatment and driving innovations that enhance therapeutic efficacy.    View the publication here: https://lnkd.in/gHGefM25    Predicine is committed to advancing cancer research and collaborates with leading pharmaceutical companies to transform insights into impactful therapies.    For additional information about Predicine and our biopharma solutions, click below to schedule a meeting with Predicine's team https://lnkd.in/gfAamv7U #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx 

10

We had a great response to our presentation of the new PARG inhibitor, NODX-010, at the EORTC-NCI-AACR meeting in Barcelona last week. Our Chief Scientific Officer, Dominic James PhD, FRSB, shared some of our latest progress in this area. It was an excellent opportunity to connect with the global oncology community and discuss the potential of NODX-010 with world-leading experts in DNA Damage Response. If you’d like a copy of the poster, you can download it using the QR code below. #NodusOncology  #CancerResearch  #Oncology #DrugDiscovery #ENASymp24

55

2 Comments

#Didyouknow? Sapient's mass spectrometry-based /𝐃𝐞𝐞𝐩/ 𝐂𝐞𝐥𝐥 𝐒𝐮𝐫𝐟𝐚𝐜𝐞 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 can be used to identify and prioritize tumor-associated antigens (#TAAs) as key targets for T cell engagers. See how we comprehensively measure up to 1,000 cell surface proteins to uncover those differentially and abundantly expressed on tumors: https://lnkd.in/g2QSTkQD #Tcellengagers #Tcells #proteomics #discoveryproteomics

22

Check out the key highlights from our recently released CGT Catapult Annual Review 2024 in the video below 👇 Read the Annual Review 2024: https://ow.ly/MA8k50ThbHZ #CellTherapy #GeneTherapy #AdvancedTherapies

21

1 Comment

Rachel Moore is Associate Principal Scientist in the High Throughput Screening group at AstraZeneca, Cambridge. Recently, Rachel has been screening to identify small molecules that target RNA. RNA is a relatively new target in small molecule drug discovery. As a target it presents exciting new opportunities, because you are affecting the resultant protein levels before the protein is even produced, thus you can target proteins that have previously been deemed undruggable. Targeting RNA also opens up a new range of targets, proteins that don’t get directed transcribed into proteins, but have important regulatory functions in health and disease. Elegant though this approach is therapeutically, it holds some major challenges for the design of drug discovery assay cascades. RNA can form two- and three-dimensional structures and affinity binding assays can be used to identify binders. Another approach is through reporter gene assays in cell-based screening to identify functional compounds. Rachel will describe the group’s experiences of high-throughput screens using these approaches, the design of screening cascades, and identification of lead compounds that has shown impact on both mRNA and protein level. Rachel will be speaking at ELRIG’s Drug Discovery 2024 on Wednesday 2nd October in the track ‘Advances in assay development and screening – supported by SLAS (Society for Laboratory Automation and Screening)’. Register now to catch her talk: https://lnkd.in/ePmtmfN9

151

1 Comment

It’s likely you won’t run out of great reasons to be a part of PEGS Europe in Barcelona, Nov. 5-7. But, just in case, here are two more: 1️⃣ At Booth #1316, we’ll be explaining how both our Cellestive discovery platform and full suite of antibody discovery services can help accelerate your research. 2️⃣ On Tuesday, Nov. 5 at a luncheon discussion, "Improving the Efficiency of Therapeutic Candidate Generation Through Multiple Discovery Pathways," we’ll be presenting our latest research data yielded from our Cellestive platform (which provides researchers with multiple pathways – including hybridoma library, primary B-cell, and guided NGS – for therapeutic antibody discovery). As usual, PEGS Europe will be a can’t-miss event, so we’ll see you there! (And if you want to get ahead of the game and schedule some meeting time with our team, just use the link below.) https://hubs.li/Q02TxCZJ0 #PEGS #AntibodyDiscovery #MeetUsAtPEGS

11

1 Comment

Looking to the future at what lies ahead in #cancerresearch, our CSO, Stefano Gullà spoke with Megan Thomas at Drug Discovery World (DDW) to discuss how Artificial Intelligence🖥will play an increasing role in both research and clinical development of next generation cancer treatments! Stefano commented 'With ongoing advances in technology, the landscape is poised for continued innovation and the development of transformative therapies that will improve patient outcomes and ultimately lead to better cancer prevention, diagnosis, and treatment strategies.' 📰 Find the Global Cancer Research Guide on page 40 in #DDW’s Summer issue 2024 here: https://bit.ly/3XGUYgl

20

TLK2 presents a promising opportunity for drug development in various cancer types, yet the lack of potent and selective TLK2 inhibitors as chemical probes has hindered the investigation of TLK2 biology. Researchers conducted a comprehensive approach to optimize a chemotype for increased potency and selectivity, culminating in the development of the inhibitor UNC-CA2-103. Learn more: https://lnkd.in/g24d8Rwy

31

Are you using a rocker in your organ-on-chip research? 🔬 Gravity-driven flow is essential in the early stages of cell culture, especially before cells fully adhere and form a coherent monolayer. Our latest study shows how using a rocker can prevent oxygen deprivation and support optimal cell morphology. Curious to learn more? Read the full technical note here: https://lnkd.in/ddVXtgNd #OrganOnChip #CellCulture #Rocker #GravityDrivenFlow #OxygenMeasurements #OxygenConcentration #O2

26